• lightrush@lemmy.caOP
    link
    fedilink
    arrow-up
    6
    arrow-down
    2
    ·
    3 days ago

    China’s biotech industry has evolved to the point that U.S. and European pharmaceutical giants in the last several months have spent billions to acquire China-developed drugs that could treat cancer if commercialized with regulatory approval. In March, British pharmaceutical giant AstraZeneca announced it will invest $2.5 billion in a research and development center in Beijing.

    In case you thought research isn’t subject to outsourcing.